GENERAL16 Sept 2026
Recently listed Molbio Diagnostics share price falls 9%: Healthcare stock loses 18.5% in 2 days after blockbuster rally | Stock Market News
Molbio Diagnostics shares fell 8.8% to ₹1,229.65 on September 16, as investors booked profits after a strong rally. The healthcare stock is down 18.5% in two sessions, but still trades over 50% above its ₹807 initial public offering (IPO) price. If you hold recently listed shares, treat such sharp swings as normal and avoid chasing the rally.
Key Statutory Highlights
- Molbio Diagnostics shares fell 8.8% to ₹1,229.65 on September 16, and the stock is down 18.5% over the last two sessions.
- Even after the fall, the stock trades more than 50% above its ₹807 IPO price, having gained 75% in the last month.
- For the April-June quarter of FY27, the company reported a consolidated net profit of ₹58.74 crore, against a net loss of ₹23.74 crore a year earlier.
Actionable Advice for Taxpayers / Founders:Before reacting to this price fall, check the company's latest reported results and your own investment goal, and avoid taking quick buy or sell calls based on a single day's move.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: